Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 3, 2011, Pages

  Wang, Jing ^a   Xia, Ting Yi ^a   Wang, Ying Jie ^a   Li, Hong Qi ^a   Li, Ping ^a   Wang, Ji Dong ^a   Chang, Dong Shu ^a   Liu, Liy Yuan ^a   Di, Yu Peng ^a   Wang, Xuan ^a   Wu, Wei Zhang ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

Author keywords

Concurrent treatment; Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs); Individualized radiotherapy; Non small cell lung cancer (NSCLC)

Indexed keywords

ACUTE TOXICITY; ADVERSE EVENTS; CONCURRENT TREATMENT; CURATIVE INTENT; EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS (EGFR-TKIS); EPIDERMAL GROWTH FACTOR RECEPTORS; EQUIVALENT DOSE; ERLOTINIB; ESOPHAGITIS; GEFITINIB; GROSS TUMOR VOLUME; LOCAL CONTROL; MEAN LUNG DOSE; MEDIAN SURVIVAL; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NORMAL TISSUE; OVERALL SURVIVAL; OVERALL SURVIVAL RATES; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PULMONARY TOXICITY; RADIATION DOSE; THROMBOCYTOPENIA; TUMOR PROGRESSIONS; TUMOR SIZE; VOLUME CONSTRAINT;

AMINO ACIDS; BIOLOGICAL ORGANS; CELLS; DISEASES; DRUG PRODUCTS; ENZYME INHIBITION; PEPTIDES; SAFETY FACTOR; TOXICITY; TUMORS;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUINAZOLINES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN;

EID: 80053580476     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.12.035     Document Type: Article

References (42)

1. J.P. Wisnivesky, M. Bonomi, and C. Henschke Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer Chest 128 2005 1461 1467 (Pubitemid 41324433)
2. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
3. S. Bral, M. Duchateau, and H. Versmessen Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy Cancer 116 2010 241 250
4. C.P. Belani, W. Wang, and D.H. Johnson Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer J Clin Oncol 23 2005 3760 3767
5. W. Pao, and V.A. Miller Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions J Clin Oncol 23 2005 2556 2568
6. J. Baselga, D. Rischin, and M. Ranson Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 2002 4292 4302 (Pubitemid 35266289)
7. M. Hidalgo, L.L. Siu, and J. Nemunaitis Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279 (Pubitemid 32591445)
8. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246 (Pubitemid 46621858)
9. T. Takahashi, N. Yamamoto, and T. Nukiwa Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer Anticancer Res 30 2010 557 563
10. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial JAMA 290 2003 2149 2158 (Pubitemid 37432975)
11. R. Perez-Soler, A. Chachoua, and L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247 (Pubitemid 41103678)
12. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
13. E.S. Kim, V. Hirsh, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial Lancet 372 2008 1809 1818
14. D.R. Spigel, M. Lin, and V. O'Neill Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer Cancer 112 2008 2749 2755 (Pubitemid 351969220)
15. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
16. T. Tanaka, A. Munshi, and C. Brooks Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity Clin Cancer Res 14 2008 1266 1273 (Pubitemid 351302576)
17. P. Chinnaiyan, S. Huang, and G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335 (Pubitemid 40524617)
18. J. Wang, T. Xia, and Y. Wang Pilot study of EGFR-TKIs in combination with radiation for patients with locally advanced and metastatic non-small lung cancer (Abstr.) Int J Radiat Oncol Biol Phys 75 Suppl. 2009 2587a
19. T. Xia, H. Li, and Q. Sun Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer Int J Radiat Oncol Biol Phys 66 2006 117 125 (Pubitemid 44175645)
20. L. Claude, D. Perol, and C. Ginestet A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: Clinical and dosimetric factors analysis Radiother Oncol 71 2004 175 181 (Pubitemid 38521186)
21. F.B. Zimmermann, H. Geinitz, and S. Schill Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer Lung Cancer 48 2005 107 114 (Pubitemid 40381006)
22. S. Wang, Z. Liao, and X. Wei Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT) Int J Radiat Oncol Biol Phys 66 2006 1399 1407
23. N. Hanna, M. Neubauer, and C. Yiannoutsos Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
24. J. Belderbos, L. Uitterhoeve, and N. van Zandwijk Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) Eur J Cancer 43 2007 114 121 (Pubitemid 46054477)
25. S. Hughes, J. Liong, and A. Miah A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study J Thorac Oncol 3 2008 648 651 (Pubitemid 351787311)
26. Rothschild S, Bucher SE, Bernier J, et al. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: A phase I trial. Int J Radiat Oncol Biol Phys. In press.
27. N.W. Choong, A.M. Mauer, and D.J. Haraf Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer J Thorac Oncol 3 2008 1003 1011
28. B. Center, W.J. Petty, and D. Ayala A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer J Thorac Oncol 5 2010 69 74
29. F.M. Kong, J.A. Hayman, and K.A. Griffith Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis Int J Radiat Oncol Biol Phys 65 2006 1075 1086 (Pubitemid 44202245)
30. W.F. Hartsell, C.B. Scott, and G.S. Dundas Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03 Am J Clin Oncol 30 2007 368 376 (Pubitemid 47356681)
31. H.M. Yu, Y.F. Liu, and J.M. Yu Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer Radiother Oncol 87 2008 29 34
32. S. Yuan, X. Sun, and M. Li A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer Am J Clin Oncol 30 2007 239 244 (Pubitemid 46884142)
33. A.T. Fernandes, J. Shen, and J. Finlay Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes Radiother Oncol 95 2010 178 184
34. E.C. Phernambucq, F.O. Spoelstra, and W.F. Verbakel Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity Ann Oncol 22 2011 132 138
35. K.H. Cho, S.J. Ahn, and H.R. Pyo A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: Results of Korean Radiation Oncology Group 0301 study Int J Radiat Oncol Biol Phys 74 2009 1397 1404
36. Y. Segawa, K. Kiura, and N. Takigawa Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007 J Clin Oncol 28 2010 3299 3306
37. N. Yamamoto, K. Nakagawa, and Y. Nishimura Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105 J Clin Oncol 28 2010 3739 3745
38. A. Auperin, C. Le Pechoux, and E. Rolland Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
39. K. Kaira, T. Takahashi, and H. Murakami Long-term survivors of more than 5 years in advanced non-small cell lung cancer Lung Cancer 67 2010 120 123
40. R. Feld, S.S. Sridhar, and F.A. Shepherd Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review J Thorac Oncol 1 2006 367 376 (Pubitemid 47163993)
41. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
42. K. Takeda, T. Hida, and T. Sato Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a west Japan thoracic oncology group trial (WJTOG0203) J Clin Oncol 28 2010 753 760